{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:14:08Z","timestamp":1790727248384,"version":"4.1.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T00:00:00Z","timestamp":1427328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0121257","type":"journal-article","created":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T13:18:23Z","timestamp":1427462303000},"page":"e0121257","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":86,"title":["Prophylactic Use of Macrolide Antibiotics for the Prevention of Chronic Obstructive Pulmonary Disease Exacerbation: A Meta-Analysis"],"prefix":"10.1371","volume":"10","author":[{"given":"Wentao","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodi","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanqi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,3,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(07)61380-4","article-title":"Global burden of COPD: risk factors, prevalence, and future trends","volume":"370","author":"DM Mannino","year":"2007","journal-title":"Lancet"},{"key":"ref2","unstructured":"World Health Organization. Chronic obstructive pulmonary disease. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/respiratory\/copd\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/respiratory\/copd\/en\/<\/ext-link>."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00136712","article-title":"Long-term macrolide treatment for chronic respiratory disease","volume":"42","author":"P Spagnolo","year":"2013","journal-title":"Eur Respir J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/thoraxjnl-2011-201518","article-title":"Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality","volume":"67","author":"S Suissa","year":"2012","journal-title":"Thorax"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"BR Celli","year":"2004","journal-title":"Eur Respir J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1378\/chest.12-1801","article-title":"Preventing acute exacerbations and hospital admissions in COPD","volume":"143","author":"N Marchetti","year":"2013","journal-title":"Chest"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa1105482","article-title":"Changes in forced expiratory volume in 1 second over time in COPD","volume":"65","author":"J Vestbo","year":"2011","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1056\/NEJMra0800353","article-title":"Infection in the pathogenesis and course of chronic obstructive pulmonary disease","volume":"359","author":"S Sethi","year":"2008","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1164\/rccm.200506-859OC","article-title":"Infections and airway inflmmation in chronic obstructive pulmonary disease severe exacerbations","volume":"173","author":"A Papi","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.rmed.2013.05.004","article-title":"A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease","volume":"107","author":"E Donath","year":"2013","journal-title":"Respir Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000350828","article-title":"Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysis","volume":"86","author":"GY Yao","year":"2013","journal-title":"Respiration"},{"key":"ref12","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.goldcopd.org\/\" xlink:type=\"simple\">http:\/\/www.goldcopd.org\/<\/ext-link>."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1378\/chest.120.3.730","article-title":"Erythromycin and common cold in COPD","volume":"120","author":"T Suzuki","year":"2001","journal-title":"Chest"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.rmed.2004.06.009","article-title":"The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD","volume":"99","author":"D Banerjee","year":"2005","journal-title":"Respir Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","article-title":"Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations","volume":"178","author":"TA Seemungal","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pupt.2009.12.002","article-title":"Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy","volume":"23","author":"F Blasi","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000321374","article-title":"Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease","volume":"80","author":"ZY He","year":"2010","journal-title":"Respiration"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"RK Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1465-9921-14-125","article-title":"Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial","volume":"14","author":"FF Berkhof","year":"2013","journal-title":"Respir Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e105609","DOI":"10.1371\/journal.pone.0105609","article-title":"The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial","volume":"9","author":"JL Simpson","year":"2014","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"S Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/31.suppl_C.1","article-title":"Chemistry and mode of action of macrolides","volume":"31","author":"T Mazzei","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"ref23","first-page":"480","article-title":"Penetration of macrolides into pulmonary sites of infection","volume":"16","author":"DT Bearden","year":"1999","journal-title":"Infect Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","article-title":"Guidelines for the management of adult lower respiratory tract infections\u2014full version","volume":"17","author":"M Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1183\/09031936.00208011","article-title":"Macrolide effects on the prevention of COPD exacerbations","volume":"40","author":"M Yamaya","year":"2012","journal-title":"Eur Respir J"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.pupt.2009.03.002","article-title":"Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis","volume":"22","author":"DF Florescu","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"key":"ref27","first-page":"751982","article-title":"The role of macrolides in noncystic fibrosis bronchiectasis","volume":"2011","author":"C Figueiredo Bde","year":"2011","journal-title":"Pulm Med"},{"key":"ref28","first-page":"CD009764","article-title":"Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)","volume":"11","author":"SC Herath","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic firosis: a double blind, placebo controlled trial","volume":"61","author":"A Clement","year":"2006","journal-title":"Thorax"},{"key":"ref30","first-page":"379","article-title":"Prospective comparative study (1994\u20131998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD","volume":"13","author":"J G\u00f3mez","year":"2000","journal-title":"Rev Esp Quimioter"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1378\/chest.12-1277","article-title":"Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial","volume":"143","author":"KF Rabe","year":"2013","journal-title":"Chest"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1365-2222.2012.03979.x","article-title":"Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments","volume":"42","author":"EJ Cameron","year":"2012","journal-title":"Clin Exp Allergy"},{"issue":"Suppl 9A","key":"ref33","first-page":"2","article-title":"Immunomodulatory properties of macrolides: overview and historical perspective","volume":"117","author":"BK Rubin","year":"2004","journal-title":"Am J Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.phrs.2011.02.001","article-title":"Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro","volume":"63","author":"N Marjanovi\u0107","year":"2011","journal-title":"Pharmacol Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1164\/rccm.201402-0207OC","article-title":"Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy","volume":"189","author":"MK Han","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"ref36","first-page":"247e57","article-title":"Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD","volume":"48","author":"M Miravitlles","year":"2012","journal-title":"Arch Bronconeumol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"f1235","DOI":"10.1136\/bmj.f1235","article-title":"Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies","volume":"346","author":"S Schembri","year":"2013","journal-title":"BMJ"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa040582","article-title":"Oral erythromycin and the risk of sudden death from cardiac causes","volume":"351","author":"WA Ray","year":"2004","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"RA Wayne","year":"2012","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0121257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T02:34:22Z","timestamp":1588991662000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0121257"}},"subtitle":[],"editor":[{"given":"James D.","family":"Chalmers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,26]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0121257","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725404799.793564098","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,26]]}}}